Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2010 1
2012 2
2013 1
2014 4
2015 4
2016 8
2017 39
2018 27
2019 24
2020 28
2021 24
2022 19
2023 26
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Clostridioides (Clostridium) difficile infection.
Oksi J, Anttila VJ, Mattila E. Oksi J, et al. Ann Med. 2020 Feb-Mar;52(1-2):12-20. doi: 10.1080/07853890.2019.1701703. Epub 2019 Dec 13. Ann Med. 2020. PMID: 31801387 Free PMC article. Review.
Recently, the treatment options of CDI have undergone major changes: current recommendations speak against using metronidazole for primary CDI, fidaxomicin and bezlotoxumab have been added to the treatment armamentarium and microbial replacement therapies have emerged. ... …
Recently, the treatment options of CDI have undergone major changes: current recommendations speak against using metronidazole for primary C …
Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.
Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Johnson S, et al. Clin Infect Dis. 2021 Sep 7;73(5):e1029-e1044. doi: 10.1093/cid/ciab549. Clin Infect Dis. 2021. PMID: 34164674
This clinical practice guideline is a focused update on management of Clostridioides difficile infection (CDI) in adults specifically addressing the use of fidaxomicin and bezlotoxumab for the treatment of CDI. This guideline was developed by a multidisciplinary panel repr …
This clinical practice guideline is a focused update on management of Clostridioides difficile infection (CDI) in adults specifically addres …
Clostridium difficile in inflammatory bowel disease.
Alhobayb T, Ciorba MA. Alhobayb T, et al. Curr Opin Gastroenterol. 2023 Jul 1;39(4):257-262. doi: 10.1097/MOG.0000000000000949. Epub 2023 May 15. Curr Opin Gastroenterol. 2023. PMID: 37265220 Review.
Strategies to prevent recurrent CDI (rCDI) include the monoclonal antibody bezlotoxumab as well as fecal microbiota transplantation (FMT). FMT has a robust profile of safety and effectiveness in preventing rCDI in adults and children. ...
Strategies to prevent recurrent CDI (rCDI) include the monoclonal antibody bezlotoxumab as well as fecal microbiota transplantation ( …
European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia JE, Goorhuis A, van Rossen TM, Ooijevaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild MJGT, Fitzpatrick F, Kuijper EJ; Guideline Committee of the European Study Group on Clostridioides difficile. van Prehn J, et al. Clin Microbiol Infect. 2021 Dec;27 Suppl 2:S1-S21. doi: 10.1016/j.cmi.2021.09.038. Epub 2021 Oct 20. Clin Microbiol Infect. 2021. PMID: 34678515 Free article.
RECOMMENDATIONS: Important changes compared with previous guideline include but are not limited to: metronidazole is no longer recommended for treatment of CDI when fidaxomicin or vancomycin are available, fidaxomicin is the preferred agent for treatment of initial CDI and the fi …
RECOMMENDATIONS: Important changes compared with previous guideline include but are not limited to: metronidazole is no longer recommended f …
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators. Wilcox MH, et al. N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615. N Engl J Med. 2017. PMID: 28121498 Free article. Clinical Trial.
Recurrences are common after antibiotic therapy. Actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxins A and B, respectively. ...The rates of initial clinical cure were 80% with bezlotoxumab alone, 73% with actoxumab plus bezlotox …
Recurrences are common after antibiotic therapy. Actoxumab and bezlotoxumab are human monoclonal antibodies against C. difficile toxi …
Update of treatment algorithms for Clostridium difficile infection.
Ooijevaar RE, van Beurden YH, Terveer EM, Goorhuis A, Bauer MP, Keller JJ, Mulder CJJ, Kuijper EJ. Ooijevaar RE, et al. Clin Microbiol Infect. 2018 May;24(5):452-462. doi: 10.1016/j.cmi.2017.12.022. Epub 2018 Jan 6. Clin Microbiol Infect. 2018. PMID: 29309934 Free article. Review.
Four phase 3 active comparator studies comparing vancomycin with bezlotoxumab, surotomycin (n = 2) and rifaximin have been published. ...
Four phase 3 active comparator studies comparing vancomycin with bezlotoxumab, surotomycin (n = 2) and rifaximin have been published. …
Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines.
Bishop EJ, Tiruvoipati R. Bishop EJ, et al. J Antimicrob Chemother. 2022 Dec 23;78(1):21-30. doi: 10.1093/jac/dkac404. J Antimicrob Chemother. 2022. PMID: 36441203 Free PMC article. Review.
Updated IDSA/SHEA and ESCMID guidelines now reflect the increased efficacy of fidaxomicin in preventing recurrence and have both promoted fidaxomicin to first-line therapy with an initial CDI episode in both non-severe and severe disease and endorsed the role of bezlotoxumab …
Updated IDSA/SHEA and ESCMID guidelines now reflect the increased efficacy of fidaxomicin in preventing recurrence and have both promoted fi …
Bezlotoxumab.
Johnson S, Gerding DN. Johnson S, et al. Clin Infect Dis. 2019 Feb 1;68(4):699-704. doi: 10.1093/cid/ciy577. Clin Infect Dis. 2019. PMID: 30020417 Review.
Despite preclinical studies suggesting efficacy for the anti-toxin A monoclonal, actoxumab, the anti-toxin B monoclonal, bezlotoxumab, alone was shown to be effective in clinical trials. Intravenous infusion of bezlotoxumab at a 10 mg/kg dosage as adjunctive treatme …
Despite preclinical studies suggesting efficacy for the anti-toxin A monoclonal, actoxumab, the anti-toxin B monoclonal, bezlotoxumab …
Bezlotoxumab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999941 Free Books & Documents. Review.
No information is available on the use of bezlotoxumab during breastfeeding. Because bezlotoxumab is a large protein molecule with a molecular weight of about 148,200 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in …
No information is available on the use of bezlotoxumab during breastfeeding. Because bezlotoxumab is a large protein molecule …
Controversies in the Prevention and Treatment of Clostridioides difficile Infection in Adults: A Narrative Review.
Bainum TB, Reveles KR, Hall RG 2nd, Cornell K, Alvarez CA. Bainum TB, et al. Microorganisms. 2023 Feb 3;11(2):387. doi: 10.3390/microorganisms11020387. Microorganisms. 2023. PMID: 36838352 Free PMC article. Review.
The oral option of fecal microbiota transplantation (FMT), SER109, and the now FDA-approved RBX2660 represent exciting new options to correct dysbiosis. Bezlotoxumab is another attractive option to prevent recurrences. Further head-to-head studies of newer agents will be n …
The oral option of fecal microbiota transplantation (FMT), SER109, and the now FDA-approved RBX2660 represent exciting new options to correc …
200 results